Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 5/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.54 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.53 |
| ▸ | NMUR2 | Q9GZQ4 | 5/20 | 0.52 |
| ▸ | NMUR1 | Q9HB89 | 5/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.52 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.52 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30930223 | 0.96 | OPRM1 (0.55) | BDKRB2OPRM1OPRD1EPHA2NMUR2 | |
| SCHEMBL29590593 | 0.96 | OPRM1 (0.55) | BDKRB2OPRM1OPRD1EPHA2NMUR2 | |
| SCHEMBL31289579 | 0.90 | BDKRB2 (0.55) | BDKRB2OPRM1OPRD1 | |
| SCHEMBL29405398 | 0.90 | BDKRB2 (0.70) | BDKRB2OPRM1OPRD1NMUR2NMUR1 | |
| Bradykinin SCHEMBL7949679 | 0.89 | BDKRB2 (0.67) | BDKRB2OPRM1OPRD1EPHA2NMUR2 | |
| Bradykinin SCHEMBL7949684 | 0.89 | BDKRB2 (0.67) | BDKRB2OPRM1OPRD1EPHA2NMUR2 | |
| SCHEMBL30672572 | 0.89 | BDKRB2 (0.72) | BDKRB2OPRM1OPRD1EPHA2NMUR2 | |
| SCHEMBL29973237 | 0.87 | BDKRB2 (0.64) | BDKRB2OPRM1OPRD1EPHA2NMUR2 | |
| SCHEMBL17887567 | 0.87 | BDKRB2 (0.64) | BDKRB2OPRM1OPRD1EPHA2NMUR2 | |
| SCHEMBL29826081 | 0.87 | MAPK8 (0.53) | OPRM1EPHA2NMUR2NMUR1MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024259525-A1 | NANOPARTICLES COMPRISING N,N,N-TRIMETHYL CHITOSAN COATED WITH PEPTIDE AGONISTS OF KININ B1 OR B2 AND/OR PEPTIDE ANTAGONISTS OF KININ B1 FOR TRANSVASCULAR DRUG DELIVERY ACROSS THE BLOOD-BRAIN BARRIER | SOCIETE DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUEE SOCPRA SANTE ET HUMAINES, S.E.C. (CA) | 2024-12-26 | — | — | WO | disclosed |
| US-12013392-B2 | Global proteomic screening of random bead arrays using mass spectrometry imaging | AMBERGEN, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-11846634-B2 | Global proteomic screening of random bead arrays using mass spectrometry imaging | AMBERGEN, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20200354404-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354404-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | DNPEP, PEPD, ANPEP | BDKRB2 281/4885OPRM1 1731/4885OPRD1 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.